For adults and children aged 2 years and older with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, eg, eGFR ≥30 mL/min/1.73 m2.
Don't wait to intervene: Rivfloza® is Now Approved for people with PH1 who are 2 years and older
Rivfloza® is available to prescribe. Want more info?
Choose Rivfloza® (nedosiran) injection: the route that delivers durable control of urinary oxalate1
Rivfloza® significantly reduces urinary oxalate (UOx) levels with a once-monthly injection, to help your patients with primary hyperoxaluria type 1 (PH1) look forward to the journey ahead.1
Understanding PH1
Early diagnosis and intervention are critical.2
Reducing UOx levels
Rivfloza® delivered rapid and durable control of urinary oxalate.1
Patient administration
Offer patients the ability to self-administer at home.1
For children aged 2 to less than 12 years, Rivfloza® may be administered by a caregiver after proper training and under the guidance and supervision of a health care professional.1
Important Safety Information for Rivfloza®
Adverse Reactions
Most common adverse reactions (reported in ≥20% of patients) are injection site reactions, which include erythema, pain, bruising, and rash.
Please click here for Rivfloza® Prescribing Information.
Important Safety Information for Rivfloza®
Adverse Reactions
Most common adverse reactions (reported in ≥20% of patients) are injection site reactions, which include erythema, pain, bruising, and rash.
Please click here for Rivfloza® Prescribing Information.
References:
- Rivfloza® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.
- Fargue S, Harambat J, Gagnadoux MF, et al. Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1. Kidney Int. 2009;76(7):767-773. doi:10.1038/ki.2009.237
- Groothoff JW, Metry E, Deesker L, et al. Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nat Rev Nephrol. 2023;19(3):194-211. doi:10.1038/s41581-022-00661-1